Issue 1-2/2013

  • IMI: Stem cells at centre-stage

    In this issue:

    Big Pharma is for the first time directly addressing the need for better disease models than those available through animal experimentation. With a €50m EU project led by Hoffmann-la Roche and the University of Oxford, the Innovative Medicines Initiative's StemBaNCC project is using stem cells to establish 1,500 human cell lines to mimic disease processes in the bodies of the ill. One of the project's goals is to lower the extremely high failure rate in screening and early clinical testing of drug candidates.

    Volume 2016

    Volume 2015

    Volume 2014

    Volume 2013

    Volume 2012

    © 2007-2016 BIOCOM

    http://www.european-biotechnology-news.com/magazine/ebsin/2013/1-2.html

    Kurszettel

    Alle Kurse

    TOP

    • NORDIC NANOVECTOR (N)31.90 NOK12.72%
    • VITA 34 (D)4.46 EUR5.69%
    • SAREUM HOLDINGS (UK)0.78 GBP5.41%

    FLOP

    • MOLOGEN (D)1.80 EUR-6.74%
    • GW PHARMACEUTICALS (UK)518.00 GBP-5.39%
    • DIAXONHIT (F)0.38 EUR-5.00%

    TOP

    • DIAMYD MEDICAL -B- (S)7.20 SEK66.7%
    • KARO BIO (S)41.60 SEK35.1%
    • NORDIC NANOVECTOR (N)31.90 NOK30.7%

    FLOP

    • BIONOR PHARMA (N)0.44 NOK-25.4%
    • MOLOGEN (D)1.80 EUR-21.7%
    • WILEX (D)1.50 EUR-13.3%

    TOP

    • NICOX (F)10.18 EUR435.8%
    • SAREUM HOLDINGS (UK)0.78 GBP254.5%
    • GENMAB (DK)1103.00 DKK80.8%

    FLOP

    • BB BIOTECH (D)45.05 EUR-83.2%
    • EVOCUTIS (UK)0.04 GBP-80.0%
    • CIRCASSIA LIMITED (L)92.75 GBP-71.7%

    No liability assumed, Date: 26.08.2016